Aceto Corp

Formerly OTC: ACETQ

Material Contracts Filter

EX-10.1
from 8-K 3 pages Amendment to Change in Control Agreement
12/34/56
EX-10.1
from 8-K 9 pages Key Executive Incentive Agreement
12/34/56
EX-10.1
from 8-K 79 pages Amended and Restated Asset Purchase Agreement by and Among Aceto Corporation, Aceto Agricultural Chemicals Corporation and Aceto Realty LLC, as Sellers, and Nmc Atlas, L.P., as Buyer Dated as of April 14, 2019
12/34/56
EX-10.2
from 8-K 14 pages Amended and Restated Mutual Release of Claims
12/34/56
EX-10.1
from 8-K 149 pages Amended and Restated Asset Purchase Agreement by and Among Rising Pharmaceuticals, Inc., Pack Pharmaceuticals, LLC, Rising Health, LLC, and Acetris Health, LLC, Collectively, as Sellers, Aceto Corporation, as Parent, and Shore Suven Pharma, Inc., as Buyer Dated as of March 31, 2019
12/34/56
EX-10.3
from 8-K 11 pages Mutual Release of Claims
12/34/56
EX-10.2
from 8-K 10 pages Shore Suven Pharma, Inc. 1100 Cornwall Road, Suite 110 Monmouth Junction, New Jersey 08852 Re: Equity Commitment Letter Ladies and Gentlemen
12/34/56
EX-10.1
from 8-K 149 pages Asset Purchase Agreement by and Among Rising Pharmaceuticals, Inc., Pack Pharmaceuticals, LLC, Rising Health, LLC, and Acetris Health, LLC, Collectively, as Sellers, Aceto Corporation, as Parent, and Shore Suven Pharma, Inc., as Buyer Dated as of March 7, 2019
12/34/56
EX-10.4
from 10-Q 8 pages Key Executive Incentive Agreement
12/34/56
EX-10.3
from 10-Q 4 pages As of February 11, 2019 Re: Retention Bonus Dear Steve
12/34/56
EX-10.2
from 10-Q 144 pages Asset Purchase Agreement by and Among Aceto Corporation, Aceto Agricultural Chemicals Corporation and Aceto Realty LLC, as Sellers, and Nmc Atlas, L.P., as Buyer Dated as of February 18, 2019
12/34/56
EX-10.2
from 10-Q 18 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Supply and Distribution Agreement
12/34/56
EX-10.65
from 10-K/A 8 pages Retention Bonus Agreement
12/34/56
EX-10.64
from 10-K/A 8 pages Retention Bonus Agreement
12/34/56
EX-10.63
from 10-K/A 2 pages The Severance Shall Be in Lieu of Any Severance Payable Pursuant to the Company’s Severance Policy, Which You Shall Cease to Be Eligible to Participate in From and After the Date Hereof. for the Avoidance of Doubt, in No Event Shall You Be Entitled to Receive Severance Pursuant to This Letter Agreement in the Event Your Employment Is Terminated on or After the Occurrence of a Change in Control (In Which Case Your Right to Receive Severance, if Any, Shall Be Governed by the Change in Control Agreement)
12/34/56
EX-10.2
from 8-K 16 pages Change in Control Agreement
12/34/56
EX-10.1
from 8-K 8 pages Material contract
12/34/56
EX-10.2
from 8-K/A 16 pages Change in Control Agreement
12/34/56
EX-10.1
from 8-K/A 7 pages § 60,000 Time-Vested Restricted Stock Awards § 35,000 Performance-Vested Restricted Stock Units Future Annual Equity Grants Will Be Awarded, With Due Regard to Your Position, at Such Time as Grants Are Generally Made to Other Senior Executives of the Company, the Amount and Term of Such Grants, if Any, Being at the Sole Discretion of the Board
12/34/56
EX-10.1
from 8-K 11 pages This Separation and General Release Agreement Must Be Executed and Delivered to the Company (Attn: Steve Rogers – Chief Legal Officer – No Later Than October 17, 2017. Separation and General Release Agreement
12/34/56